TAVR for severe aortic regurgitation using VitaFlow Liberty
Part of Heart & circulation clinical trials.
This trial tests the VitaFlow Liberty device, a catheter-based treatment for people with severe aortic regurgitation (a leaky heart valve). If you have symptoms or your heart is starting to weaken, this procedure might help avoid open-heart surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 60 or older.
- You have moderate-to-severe or severe aortic regurgitation that is causing symptoms or showing signs of heart stress (like low heart pumping ability or enlarged heart).
- Your heart team has confirmed your valve is shaped well for this catheter-based procedure.
- You are willing and able to come back for follow-up visits over time.
- You do not have other severe heart valve problems, kidney failure, or allergies to required blood thinners or contrast dye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new valve replacement procedure (TAVR) is safe and effective for people with severe aortic regurgitation, a leaky heart valve. It is designed for patients who are not good candidates for open-heart surgery because of other health conditions.
This trial tests a less invasive heart valve replacement (TAVR) for people with a leaky aortic valve (aortic regurgitation). It uses ultrasound guidance to place the new valve, which may offer a treatment option for those who cannot have open-heart surgery.
This trial tests whether a 3D computer simulation can help guide a less invasive procedure (TAVR) to replace a leaky aortic valve. It may be an option for people with severe aortic regurgitation who are at least 65 years old.
This trial is testing a less invasive procedure (TAVR) to fix a leaky aortic valve without open-heart surgery. It's for people with severe aortic regurgitation who are either having symptoms or showing signs of heart strain, and who are not good candidates for traditional surgery.
This trial compares a new catheter-based valve (J-Valve) with open-heart surgery for people with severe aortic regurgitation, a condition where the aortic valve doesn't close tightly. It aims to see which treatment is safer and more effective.
This study is testing a new, less invasive heart valve system (TaurusTrio) for people with severe aortic regurgitation (a leaky aortic valve) who cannot have open-heart surgery. It aims to see if the valve is safe and works well to improve symptoms.
Hear when a new Aortic Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.